** Shares of drug developer BioAge Labs crater 67.6% to $6.52 in extended trading
** Co discontinues mid-stage trial of its experimental obesity drug after high levels of certain liver enzymes observed in some patients
** BioAge's experimental drug, azelaprag, mimics activity of the exerkine apelin, a peptide released in response to exercise due to muscle contraction
** Co was studying azelaprag as a monotherapy and in combination with Eli Lilly's tirzepatide
** BioAge has stopped dosing all patients and plans to further analyze data from people who have been enrolled
** As of last close, stock down ~10% since its market debut in September
(Reporting by Juveria Tabassum in Bengaluru)
((Juveria.Tabassum@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。